Literature DB >> 28646614

Does breast MRI background parenchymal enhancement indicate metabolic activity? Qualitative and 3D quantitative computer imaging analysis.

Eralda Mema1, Victoria L Mango2, Xiaotao Guo1, Jenika Karcich1, Randy Yeh1, Ralph T Wynn1, Binsheng Zhao1, Richard S Ha1.   

Abstract

PURPOSE: To investigate whether the degree of breast magnetic resonance imaging (MRI) background parenchymal enhancement (BPE) is associated with the amount of breast metabolic activity measured by breast parenchymal uptake (BPU) of 18F-FDG on positron emission tomography / computed tomography (PET/CT).
MATERIALS AND METHODS: An Institutional Review Board (IRB)-approved retrospective study was performed. Of 327 patients who underwent preoperative breast MRI from 1/1/12 to 12/31/15, 73 patients had 18F-FDG PET/CT evaluation performed within 1 week of breast MRI and no suspicious findings in the contralateral breast. MRI was performed on a 1.5T or 3.0T system. The imaging sequence included a triplane localizing sequence followed by sagittal fat-suppressed T2 -weighted sequence, and a bilateral sagittal T1 -weighted fat-suppressed fast spoiled gradient-echo sequence, which was performed before and three times after a rapid bolus injection (gadobenate dimeglumine, Multihance; Bracco Imaging; 0.1 mmol/kg) delivered through an IV catheter. The unaffected contralateral breast in these 73 patients underwent BPE and BPU assessments. For PET/CT BPU calculation, a 3D region of interest (ROI) was drawn around the glandular breast tissue and the maximum standardized uptake value (SUVmax ) was determined. Qualitative MRI BPE assessments were performed on a 4-point scale, in accordance with BI-RADS categories. Additional 3D quantitative MRI BPE analysis was performed using a previously published in-house technique. Spearman's correlation test and linear regression analysis was performed (SPSS, v. 24). RESULT: The median time interval between breast MRI and 18F-FDG PET/CT evaluation was 3 days (range, 0-6 days). BPU SUVmax mean value was 1.6 (SD, 0.53). Minimum and maximum BPU SUVmax values were 0.71 and 4.0. The BPU SUVmax values significantly correlated with both the qualitative and quantitative measurements of BPE, respectively (r(71) = 0.59, P < 0.001 and r(71) = 0.54, P < 0.001). Qualitatively assessed high BPE group (BI-RADS 3/4) had significantly higher BPU SUVmax of 1.9 (SD = 0.44) compared to low BPE group (BI-RADS 1/2) with an average BPU SUVmax of 1.17 (SD = 0.32) (P < 0.001). On linear regression analysis, BPU SUVmax significantly predicted qualitative and quantitative measurements of BPE (β = 1.29, t(71) = 3.88, P < 0.001 and β = 19.52, t(71) = 3.88, P < 0.001).
CONCLUSION: There is a significant association between breast BPU and BPE, measured both qualitatively and quantitatively. Increased breast cancer risk in patients with high MRI BPE could be due to elevated basal metabolic activity of the normal breast tissue, which may provide a susceptible environment for tumor growth. LEVEL OF EVIDENCE: 3 Technical Efficacy: Stage 3 J. Magn. Reson. Imaging 2018;47:753-759.
© 2017 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  BPE; BPU; PET

Mesh:

Substances:

Year:  2017        PMID: 28646614     DOI: 10.1002/jmri.25798

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  8 in total

1.  Fully Automated Convolutional Neural Network Method for Quantification of Breast MRI Fibroglandular Tissue and Background Parenchymal Enhancement.

Authors:  Richard Ha; Peter Chang; Eralda Mema; Simukayi Mutasa; Jenika Karcich; Ralph T Wynn; Michael Z Liu; Sachin Jambawalikar
Journal:  J Digit Imaging       Date:  2019-02       Impact factor: 4.056

Review 2.  Background parenchymal enhancement on breast MRI: A comprehensive review.

Authors:  Geraldine J Liao; Leah C Henze Bancroft; Roberta M Strigel; Rhea D Chitalia; Despina Kontos; Linda Moy; Savannah C Partridge; Habib Rahbar
Journal:  J Magn Reson Imaging       Date:  2019-04-19       Impact factor: 4.813

3.  Multiparametric 18F-FDG PET/MRI of the Breast: Are There Differences in Imaging Biomarkers of Contralateral Healthy Tissue Between Patients With and Without Breast Cancer?

Authors:  Doris Leithner; Thomas H Helbich; Blanca Bernard-Davila; Maria Adele Marino; Daly Avendano; Danny F Martinez; Maxine S Jochelson; Panagiotis Kapetas; Pascal A T Baltzer; Alexander Haug; Marcus Hacker; Yasemin Tanyildizi; Elizabeth A Morris; Katja Pinker
Journal:  J Nucl Med       Date:  2019-06-28       Impact factor: 10.057

4.  The progesterone-receptor modulator, ulipristal acetate, drastically lowers breast cell proliferation.

Authors:  Carolyn L Westhoff; Hua Guo; Zhong Wang; Hanina Hibshoosh; Margaret Polaneczky; Malcolm C Pike; Richard Ha
Journal:  Breast Cancer Res Treat       Date:  2022-01-11       Impact factor: 4.624

5.  Metabolic Activity of Normal Glandular Tissue on 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography: Correlation with Menstrual Cycles and Parenchymal Enhancements.

Authors:  Young-Sil An; Yongsik Jung; Ji Young Kim; Sehwan Han; Doo Kyoung Kang; Seon Young Park; Tae Hee Kim
Journal:  J Breast Cancer       Date:  2017-12-19       Impact factor: 3.588

6.  A multiparametric [18F]FDG PET/MRI diagnostic model including imaging biomarkers of the tumor and contralateral healthy breast tissue aids breast cancer diagnosis.

Authors:  Doris Leithner; Joao V Horvat; Blanca Bernard-Davila; Thomas H Helbich; R Elena Ochoa-Albiztegui; Danny F Martinez; Michelle Zhang; Sunitha B Thakur; Georg J Wengert; Anton Staudenherz; Maxine S Jochelson; Elizabeth A Morris; Pascal A T Baltzer; Paola Clauser; Panagiotis Kapetas; Katja Pinker
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-06-13       Impact factor: 9.236

7.  Ipsilateral Recurrence of DCIS in Relation to Radiomics Features on Contrast Enhanced Breast MRI.

Authors:  Ga Eun Park; Sung Hun Kim; Eun Byul Lee; Yoonho Nam; Wonmo Sung
Journal:  Tomography       Date:  2022-03-01

8.  Background Parenchymal Enhancement on Breast MRI as a Prognostic Surrogate: Correlation With Breast Cancer Oncotype Dx Score.

Authors:  Michelle Zhang; Meredith Sadinski; Dana Haddad; Min Sun Bae; Danny Martinez; Elizabeth A Morris; Peter Gibbs; Elizabeth J Sutton
Journal:  Front Oncol       Date:  2021-02-04       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.